Clinical trials: sponsored by Regeneron Pharmaceuticals
Atopic Dermatitis
Study to Assess the Long-term Safety of Dupilumab Administered in Participants ≥6 Months to <18 Years of Age With Atopic Dermatitis (AD)
The primary objective of the study is to assess the long-term safety of dupilumab in pediatric participants with AD. The secondary objectives of the study are: To assess the long-term efficacy of dupilumab in pediatric…
- Trial name
- NCT02612454
- Testing
- Dupilumab
- Where
- 84 sites in United States, Canada and 5 more
- Volunteers
- 880 people
- Sponsor
- Regeneron Pharmaceuticals
Non Small Cell Lung Cancer, NSCLC
A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)
This study will enroll adult participants with early-stage (stage II-IIIB) non-small cell lung cancer (NSCLC) for whom surgery is planned, in the resectable NSCLC portion.
- Trial name
- NCT06465329
- Testing
- Cemiplimab, Platinum-based chemotherapy, Marlotamig
- Where
- 47 sites in United States, Brazil and 4 more
- Volunteers
- 184 people
- Sponsor
- Regeneron Pharmaceuticals
Metastatic Castration-Resistant Prostate Cancer (mCRPC), Clear Cell Renal Cell Carcinoma (ccRCC)
A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors
The main purpose of this study is to determine the safety, tolerability (how the body reacts to the drug[s]) and effectiveness (ability to treat the cancer) of REGN5678 (Nezastomig) alone, or in combination with cemiplimab.
- Trial name
- NCT03972657
- Testing
- REGN5678, Cemiplimab
- Where
- 26 sites in United States, South Korea
- Volunteers
- 345 people
- Sponsor
- Regeneron Pharmaceuticals
Metabolic Dysfunction-Associated Steatotic Liver Disease, MASLD
Trial to Evaluate ALN-CIDEB in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
This study will test a Regeneron study drug called ALN-CIDEB to find out whether it may help treat a liver disease called metabolic dysfunction-associated steatohepatitis (MASH).
- Trial name
- NCT07854782
- Testing
- ALN-CIDEB
- Where
- United States
- Volunteers
- 1,500 people
- Sponsor
- Regeneron Pharmaceuticals
Non-small Cell Lung Cancer
An Observational Study to Assess the Effectiveness and Safety of a Cemiplimab in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) in Routine Clinical Practice Settings in Europe
This study is focused on patients with non-small cell lung cancer (NSCLC) and have been prescribed a cemiplimab (Libtayo®) based treatment regimen under standard care.
- Trial name
- CEMI-LUNG (NCT05363319)
- Testing
- Cemiplimab, Platinum-based chemotherapy
- Where
- 46 sites in Austria, France and 3 more
- Volunteers
- 509 people
- Sponsor
- Regeneron Pharmaceuticals
Locally Advanced Basal Cell Carcinoma
A Study Comparing Cemiplimab-based Treatments for Adult Participants With Locally Advanced Basal Cell Skin Cancer (laBCC)
This study will test an experimental Regeneron drug called cemiplimab ("study drug") given alone or in combination with other anti-cancer drugs ("combination treatment") to see if they can help treat laBCC.
- Trial name
- NCT07808515
- Testing
- Cemiplimab, Vidutolimod, Fianlimab
- Volunteers
- 135 people
- Sponsor
- Regeneron Pharmaceuticals
Newly Diagnosed Amyloidosis, Amyloidosis Stage I-IIIA
Linvoseltamab Versus Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone (Dara-Vcd) in Adult Participants With Newly Diagnosed Systemic Light Chain Amyloidosis
This study is researching a Regeneron drug called linvoseltamab ("study drug") alone compared to standard of care (SoC) combination to see if it can help treat participants who are newly diagnosed and previously untreated for…
- Trial name
- LINKER-AL1 (NCT07901725)
- Testing
- Linvoseltamab, Daratumumab, Bortezomib
- Volunteers
- 382 people
- Sponsor
- Regeneron Pharmaceuticals
Generalized Myasthenia Gravis
A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis
This study is researching the experimental drugs called pozelimab and cemdisiran, and cemdisiran monotherapy. The study is focused on patients with generalized Myasthenia Gravis (gMG).
- Trial name
- NIMBLE (NCT05070858)
- Testing
- Pozelimab + Cemdisiran, Cemdisiran, Pozelimab
- Where
- 116 sites in United States, Belgium and 17 more
- Volunteers
- 288 people
- Sponsor
- Regeneron Pharmaceuticals
Diabetic Kidney Disease (DKD)
Study to Assess the Effects of ALN-ANG3 in Adult Participants With Diabetic Kidney Disease
This study is researching an experimental drug called ALN-ANG3 (called "study drug"). The study is focused on participants who have diabetic kidney disease.
- Trial name
- ANCHOR-POC (NCT07271186)
- Testing
- ALN-ANG3, Evinacumab
- Where
- 59 sites in United States
- Volunteers
- 195 people
- Sponsor
- Regeneron Pharmaceuticals
Lipodystrophy, Generalized Lipodystrophy (GLD)
Compassionate Use or Expanded Access of Mibavademab
Provide Expanded Access to REGN4461 for patients with diseases associated with deficient leptin signaling.
- Conditions
- Lipodystrophy, Generalized Lipodystrophy (GLD), Monogenic Obesity (MOB)
- Trial name
- NCT04710056
- Testing
- REGN4461
- Sponsor
- Regeneron Pharmaceuticals
Lupus Nephritis (LN)
Dose Escalation Study With Bispecific Antibodies in Adult Participants With Lupus Nephritis
This study is researching a particular group of experimental drugs administered for a short period in the treatment of participants with Lupus Nephritis (LN).
- Trial name
- NCT06975787
- Testing
- Vonsetamig, Odronextamab
- Where
- 20 sites in United States, France and 4 more
- Volunteers
- 90 people
- Sponsor
- Regeneron Pharmaceuticals
Clonal Cytopenia of Undetermined Significance (CCUS), Low-Risk Myelodysplastic Syndrome (LR-MDS)
Safety and Tolerability of REGN17235 in Adult Participants With Clonal Cytopenia of Undetermined Significance and Low-Risk Myelodysplastic Syndrome With SF3B1 Mutation
This study will test a study drug called REGN17235 (the "study drug") to see if it can help treat Clonal Cytopenia of Undetermined Significance (CCUS) and Low-Risk Myelodysplastic Syndrome (LR-MDS) with a specific genetic…
- Trial name
- NCT07753148
- Testing
- REGN17235
- Where
- 2 sites in Belgium
- Volunteers
- 52 people
- Sponsor
- Regeneron Pharmaceuticals
Relapsed/Refractory Multiple Myeloma (RRMM)
Adult Outpatient Linvoseltamab With Tocilizumab Prophylaxis to Mitigate the Risk of Cytokine Release Syndrome (CRS)
This study is researching whether the use of tocilizumab before the first dose of linvoseltamab will decrease the risk of Cytokine Release Syndrome (CRS) in participants who have Relapsed or Refractory Multiple Myeloma (RRMM) who…
- Trial name
- POPLIN (NCT07609940)
- Testing
- Linvoseltamab, Tocilizumab
- Where
- 7 sites in United States
- Volunteers
- 30 people
- Sponsor
- Regeneron Pharmaceuticals
Pulmonary Arterial Hypertension (PAH)
Study of REGN13335 in Adult Participants With Pulmonary Arterial Hypertension (PAH)
This study is researching an experimental drug called REGN13335. The study is focused on participants with Pulmonary Arterial Hypertension (PAH).
- Trial name
- ILLUMINATE (NCT07318597)
- Testing
- REGN13335
- Where
- 33 sites in United States, Australia and 8 more
- Volunteers
- 99 people
- Sponsor
- Regeneron Pharmaceuticals
Overweight or Obesity
Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without Diabetes
This study will test an experimental drug called olatorepatide ("study drug") to determine how safe and effective this drug is compared to placebo and how easily the body can accept this drug at different doses and dosing…
- Trial name
- NCT07685808
- Testing
- Olatorepatide
- Where
- 21 sites in United States
- Volunteers
- 360 people
- Sponsor
- Regeneron Pharmaceuticals
Fibrodysplasia Ossificans Progressiva (FOP)
An Expanded Access Program of Garetosmab in Adult Patients With Fibrodysplasia Ossificans Progressiva (FOP)
The objective of this Expanded Access Program (EAP) is to provide garetosmab to adult patients with Fibrodysplasia Ossificans Progressiva (FOP), including patients who have completed the double-blind treatment period of the…
- Trial name
- NCT07301450
- Testing
- Garetosmab
- Sponsor
- Regeneron Pharmaceuticals
Melanoma
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
This study is researching an experimental drug called fianlimab (also known as REGN3767), combined with another medication called cemiplimab (also known as REGN2810), called "study drugs".
- Trial name
- NCT06246916
- Testing
- fianlimab, cemiplimab, relatlimab+nivolumab
- Where
- 113 sites in United States, Canada
- Volunteers
- 560 people
- Sponsor
- Regeneron Pharmaceuticals
Overweight or Obesity Without Diabetes
Efficacy And Safety of Olatorepatide in Adults With Overweight or Obesity Without Diabetes
This study will test olatorepatide (study drug) to determine whether it can help treat overweight or obesity. In this study we will test how safe and how well olatorepatide works compared to placebo in people who are overweight…
- Trial name
- RISE-1 (NCT07896265)
- Testing
- Olatorepatide
- Volunteers
- 3,000 people
- Sponsor
- Regeneron Pharmaceuticals
Multiple Myeloma
Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma
The main purpose of this study is to learn about the safety of linvoseltamab and to find out what is the best dose of linvoseltamab to give to patients with multiple myeloma and to look for any signs that linvoseltamab can…
- Trial name
- LINKER-MM1 (NCT03761108)
- Testing
- Linvoseltamab
- Where
- 40 sites in United States, Belgium and 5 more
- Volunteers
- 387 people
- Sponsor
- Regeneron Pharmaceuticals
Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Study to Evaluate ALN-CIDEB in Adults With Fibrotic Metabolic Dysfunction-Associated Steatohepatitis (MASH)
This study will test a Regeneron study drug called ALN-CIDEB to find out whether it may help treat a liver disease called MASH. In this study, researchers are looking at the effect of ALN-CIDEB on reducing liver fat, liver…
- Trial name
- NCT07631637
- Testing
- ALN-CIDEB
- Where
- 16 sites in United States, Puerto Rico
- Volunteers
- 150 people
- Sponsor
- Regeneron Pharmaceuticals